



October 20-22, 2024
Loews Chicago Hotel



ASSOCIATION OF AMERICAN CANCER INSTITUTES
CME jointly provided by the American Association for Cancer
Research and the Association of American Cancer Institutes.

Program Committee

Chair: Kelvin Lee, MD

*Indiana University Melvin and Bren Simon
Comprehensive Cancer Center*

John Carpten, PhD

City of Hope Comprehensive Cancer Center

Jenny Chang, MD

*Houston Methodist Dr. Mary and Ron Neal
Cancer Center*

Nicholas Fisher, MBA

Siteman Cancer Center

Loriana Hernández-Aldama

ArmorUp for LIFE®

Andrew Mesecar, PhD

*Purdue University Institute for
Cancer Research*

Jennifer W. Pegher, MA, MBA

Association of American Cancer Institutes

Yolanda Sanchez, PhD

*University of New Mexico
Comprehensive Cancer Center*

Julie C. Schaum, MS

Vanderbilt-Ingram Cancer Center

Barry P. Sleckman, MD, PhD

*O'Neal Comprehensive Cancer Center at
the University of Alabama at Birmingham*

Alex Zafirovski, MBA, RT(T) ARRT

*Robert H. Lurie
Comprehensive Cancer Center of
Northwestern University*

Meeting App and Social Media

The agenda, presentations, exhibitor information, and attendees list are available on the meeting app. To access the app:

- Download “Cvent Events” from your mobile app store.
- Log in with the name and email used during registration.
- You will receive a 6-digit verification code. Enter your code and log in.
- Within the Cvent Events app, search for “2024 AACI/CCAF Annual Meeting” and download the meeting. The meeting app can also be accessed on your desktop at: <https://cvent.me/MVqwQk>.

X: @AACI_Cancer

Facebook: AACICancer

Instagram: @AACICancer

LinkedIn: <https://linkedin.com/company/aaci-cancer>

Hashtag: #AACI2024

Wireless Network: AACI

Password: AACI2024!

Welcome

Welcome to the 2024 AACI/CCAF Annual Meeting! This three-day meeting offers AACI members an opportunity to network with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges. This year's conference also featured a pre-event meeting for new cancer center directors and the 2024 Diversity, Equity, and Inclusion (DEI) Summit, hosted in partnership with the American Cancer Society and the Cancer Center DEI Network.

I'd like to extend a warm welcome to the new members of AACI's Board of Directors, Drs. B. Mark Evers, Kelvin Lee, and Thomas A. Sellers. I'd also like to express AACI's deep appreciation for outgoing board members, Drs. Marcia Cruz-Correa, Ruben A. Mesa, and Robert H. Vonderheide.

We are pleased to recognize Dr. Paula D. Bos with this year's Distinguished Scientist Award. Dr. Bos will share highlights of her research on the tumor microenvironment, particularly in relation to breast cancer. We will also present the AACI Champion for Cures Award to the Friends of Dartmouth Cancer Center, which has funded innovative cancer research, education programs, and holistic patient care through its signature event, the Prouty. The AACI Cancer Health Equity Award will be presented posthumously to Dr. Edith P. Mitchell to recognize her commitment to promoting health equity and to honor her remarkable legacy.

This year's meeting program features a keynote by Dr. Lawrence H. Einhorn, who is best known for his role in developing a curative treatment for testicular cancer. Panel discussions will highlight diverse topics, including bioengineering, mental health, patient advocacy, academic integrity and public trust, and the legal implications of DEI programs at cancer centers. As always, AACI's basic science cancer center members will share their pioneering research and representatives from the National Cancer Institute will provide updates.

The program was jointly formulated by AACI and the Association of Cancer Center Administrators (ACCA), formerly known as the Cancer Center Administrators Forum (CCAF). I am thankful for the hard work and expertise of the 2024 AACI/CCAF Annual Meeting Program Committee and to Dr. Kelvin Lee, who chaired the committee. Thanks also to the AACI staff who helped make this meeting possible.

Sincerely,
Jennifer W. Pegher, MA, MBA
Executive Director

Agenda

All sessions will be held in the Wright Ballroom, except where indicated.

Sunday, October 20

1:00 pm **Welcome and AACI Business Meeting**

Jennifer W. Pegher

Association of American Cancer Institutes

Dr. Robert A. Winn

VCU Massey Comprehensive Cancer Center

David M. Gosky

*The Ohio State University Comprehensive Cancer Center –
The James*

Alex Zafirovski

*Robert H. Lurie Comprehensive Cancer Center of
Northwestern University*

Dr. Kelvin Lee

*Indiana University Melvin and Bren Simon
Comprehensive Cancer Center*

1:45 pm **Keynote | Development of Innovative Therapies in Oncology With Testis Cancer as a Model**

During his 50-year career, Dr. Lawrence H. Einhorn has witnessed and participated in major milestones in the fight against cancer. Dr. Einhorn will discuss the concept of innovation and how it has been applied to advances in oncology, including his development, in 1974, of a chemotherapy regimen that dramatically improved the cure rate of testicular cancer. In addition to his own career accomplishments, Dr. Einhorn will highlight more recent progress, including the development of personalized targeted therapies and major advances in immunotherapy.

Dr. Larry Einhorn

*Indiana University Melvin and Bren Simon
Comprehensive Cancer Center*

2:45 pm **Networking Break** **Supported by Adminformatics** Wright Foyer

**3:15 pm 12th Annual AACI PCLl Meeting | AI and Big Data:
A New Era in Cancer Care and Research**

As we enter a new era of technological advancement, the integration of artificial intelligence (AI) and big data is poised to revolutionize cancer care. Attendees will gain valuable insights into the current and future applications of AI and big data in oncology, as well as practical knowledge on how to integrate these technologies into their own research and clinical practices. This session aims to inspire collaboration and innovation, paving the way for groundbreaking advancements in the fight against cancer.

Moderator: Dr. Christopher Lieu
University of Colorado Cancer Center

Dr. Warren Kibbe
National Cancer Institute

Dr. Travis Zack
UCSF Helen Diller Family Comprehensive Cancer Center

4:15 pm Bioengineering in Cancer: Into the Future

Our rapidly expanding knowledge base around cancer biology and cell behavior has opened the door to increasingly effective engineering applications in cancer research. Panelists will explore a range of potential cancer bioengineering breakthroughs, including in the areas of imaging, cancer detection and therapy, bioinformatics, and nanotechnology.

Moderator: Dr. Rohit Bhargava
Cancer Center at Illinois

Dr. Stephen Boppart
Cancer Center at Illinois

Dr. Gabriel Kwong
Winship Cancer Institute of Emory University

Dr. Eytan Ruppin
National Cancer Institute

4:15 pm CCAF Business Meeting

Sullivan Ballroom C

6:00 pm President's Reception

With support from Lilly

Lakeview Lawn

Agenda

Monday, October 21

7:00 am Breakfast

Sullivan Ballroom AB

7:00 am AACI Cancer Center Directors Breakfast (closed session)

Sullivan Ballroom C

8:30 am Mental Health: The Silent Side Effect of Cancer

Mental health impacts cancer patients in every phase of treatment, following them well into remission. After finishing their treatments, many patients feel lost and may struggle with serious mental health diagnoses, such as depression and PTSD. Panelists will discuss the impact of cancer on mental health, disparities in treatment options across cancer centers and income levels, and potential solutions to help ease the mental burden of cancer.

Moderator: Loriana Hernández-Aldama

ArmorUp for LIFE®

Dr. Dana Cattani

Cancer Support Community, South Central Indiana

Dr. Shawna Ehlers

Mayo Clinic Comprehensive Cancer Center

Shelley Fuld Nasso

National Coalition for Cancer Survivorship

Wenora Johnson

Patient advocate

9:45 am Mapping the Future of Patient Navigation

Patient navigation has become an essential piece of the health care puzzle in the United States, where it is used to address disparities in the accessibility and affordability of health care. With the recent introduction of billing codes to cover the cost of services, patient navigation is helping patients across the cancer continuum, from screening and diagnosis to treatment and survivorship. Patients and other experts will share their perspectives on patient navigation, along with strategies for improving the navigation experience.

Moderator: Dr. Alan Balch

National Patient Advocate Foundation

Dr. Harold P. Freeman

Ralph Lauren Center for Cancer Care and Prevention in New York City

Dr. Shanthi Sivendran

American Cancer Society

10:45 am **Break**
Supported by The Ohio State University
Comprehensive Cancer Center – The James
Wright Foyer

11:00 am **AACI Awards Presentation**
2024 AACI Cancer Health Equity Award
Dr. Edith P. Mitchell
Sidney Kimmel Comprehensive Cancer Center at Jefferson

2024 AACI Champion for Cures Award
Friends of Dartmouth Cancer Center
Dartmouth Cancer Center

11:15 am **2024 AACI Distinguished Scientist Award**
Dr. Paula D. Bos
VCU Massey Comprehensive Cancer Center

12:15 pm **Lunch**
Sullivan Ballroom

1:15 pm **Networking Dessert**

1:45 pm **Establishing Academic Integrity and Public Trust in the Misinformation Era**

In an era of increasing health misinformation, it is more important than ever to craft messages that help academic and medical institutions secure—and in some cases, regain—public trust. Panelists will explore the question of what life would be like without cancer research and share tips on delivering complex information in clear, simple terms to enhance the public’s understanding of why clinical research is important and how it has helped accelerate progress against cancer.

Moderator: Dr. Krista Longtin
*Indiana University Melvin and Bren Simon
Comprehensive Cancer Center*

Dr. Prajakta Adsul
University of New Mexico Comprehensive Cancer Center

Dr. Carrie Cameron
The University of Texas MD Anderson Cancer Center

Dr. William Dalton
Moffitt Cancer Center

Jenny Luray
Research!America

Agenda

2:30 pm AACI Government Relations Forum

Pullman

(Session not CME accredited; pre-registration required)

The Government Relations Forum provides an opportunity for attendees to network and discuss timely public policy topics. The meeting will feature compelling speakers from government, consulting firms, and AACI cancer centers.

2:45 pm Drivers of Innovation and Technology to Improve Cancer Outcomes

AACI's basic science center members focus on laboratory research and translate their findings to better cancer treatments. Directors from these centers will highlight innovative research discoveries that are accelerating progress against cancer.

Moderator: Dr. Andrew Mesecar

Purdue University Institute for Cancer Research

Dr. Reuben Shaw

Salk Institute Cancer Center

Dr. David Tuveson

Cold Spring Harbor Laboratory Cancer Center

Dr. Matthew Vander Heiden

Koch Institute for Integrative Cancer Research at MIT

3:45 pm Break

**Supported by The Ohio State University
Comprehensive Cancer Center – The James**

Wright Foyer

4:00 pm Beyond Nuts and Bolts: Evaluating the Shifting Landscape of the CCSG

Moderator: Nick Fisher

Siteman Cancer Center

Dr. Leona Flores

Salk Institute Cancer Center

Dr. Wendy Law

Fred Hutch Cancer Center

Julie Schaum

Vanderbilt-Ingram Cancer Center

Aaron Schilz

Masonic Cancer Center, University of Minnesota

Kate Shumate

UCSF Helen Diller Family Comprehensive Cancer Center

Alex Zafirovski

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

5:00 pm Vendor Presentation: Medidata

Sullivan Ballroom C
(Session not CME accredited)

Gain insight into Medidata's expanded vision and innovative support for academic clinical trials, including enhanced security measures and competitive strategies for running investigator-initiated trials on Rave. Participants will learn about Medidata's commitment to helping clients optimize their clinical trial infrastructure through system consolidation and improved reporting capabilities. The presentation will provide a comprehensive overview of how Medidata's renewed engagement model is designed to support the evolving needs of academic clinical trials.

8:00 pm Sip and Socialize With Deep 6 AI and Yunu

Pullman/The Dining Car

Tuesday, October 22

7:00 am Breakfast

Sullivan Ballroom

8:00 am Maximizing Resources to Advance Clinical Research

As cancer centers struggle to keep funds flowing, institutional leaders are searching for creative and efficient methods for conducting cancer clinical trials. Panelists will discuss how they are navigating the changing landscape of clinical research at their cancer centers. They will cover topics such as diversifying a center's clinical trial portfolio to balance revenue-generating trials with innovative—but costly—research; recruiting and retaining staff; and leveraging multidisciplinary teams to serve patients who are enrolled in trials.

Co-moderator: Dr. Barry Sleckman

O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham

Co-moderator: Nick Fisher

Siteman Cancer Center

Amy Overby

Winship Cancer Institute of Emory University

Erin Williams

*Simmons Comprehensive Cancer Center
UT Southwestern Medical Center*

Robert Wynne

Abramson Cancer Center of the University of Pennsylvania

Agenda

9:00 am **Update on the NCI Cancer Centers Program**

Dr. Krzysztof Ptak will lead a discussion about the National Cancer Institute's (NCI) goals for the national cancer research enterprise and provide updates on NCI funding at AACI cancer centers.

Dr. Krzysztof Ptak
National Cancer Institute

10:00 am **Break** **Supported by The Ohio State University Comprehensive Cancer Center – The James** Wright Foyer

10:15 am **Strategies for Enhancing Diversity in a Shifting Legal Landscape**

In response to recent laws and legal rulings related to diversity, equity, and inclusion (DEI), cancer centers must address new challenges. This session will discuss strategies for how cancer centers can gain a clear understanding of the impacts of recent DEI-related laws and enhance the diversity of their research workforce to achieve the cancer center's mission.

Co-moderator: Dr. John Carpten
City of Hope Comprehensive Cancer Center

Co-moderator: Alex Zafirovski
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Dr. Brian Gonzalez
Moffitt Cancer Center

Kevin Williams
National Institutes of Health

11:15 am **National Cancer Institute Director's Report**

Dr. W. Kimryn Rathmell
National Cancer Institute

12:15 pm **Adjourn**

Continuing Medical Education

Joint Providership Statement

Jointly provided by the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI).

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research (AACR) and Association of American Cancer Institutes (AACI). AACR is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation

AACR has designated this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)[™] for this live continuing medical education activity must complete the online CME Request for Credit Survey by Friday, November 15, 2024. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 Medical Knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME's Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

Despite enormous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States alone, it is predicted that more than 600,000 people will die from some form of cancer in 2024, making it the second most common cause of death after heart disease.

Continuing Medical Education

With the quickening pace of discoveries in basic, translational, and clinical research, the battle against cancer is rapidly moving forward. This is due in large part to the advent of new technologies, such as liquid biopsies, and our growing knowledge about how to activate the immune system to develop new immunotherapies. However, understanding and combating cancer requires leadership armed with up-to-date information about advanced technology and proven methods for its implementation.

Planned Goals and Objectives for the Education

Researchers, physicians, and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to faculty and staff at their cancer centers. As part of the program's learning objectives, all attendees should be able to describe and discuss:

- Strategies that improve the patient navigation experience
 - The impact of cancer on mental health and potential solutions to help ease the mental burden of cancer
 - Research at basic science cancer centers
 - Models implemented at cancer centers to achieve more efficient methods for conducting research and clinical trials
 - Compliance with current National Cancer Institute Cancer Center Support Grant guidelines
 - The intersection between federal and state diversity, equity, and inclusion policies, and the impact they have on cancer centers
 - The delivery of complex information in clear, simple terms to enhance the public's understanding of clinical research and how it accelerates progress against cancer
-

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products or services used by or on patients. All the relevant financial relationships for these individuals have been mitigated.

Americans With Disabilities Act

It is the policy of AACR and AACI not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please add a note on your registration form.

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants and will be disclosed at the meeting.

Questions About CME?

Please contact the Office of CME at 215-440-9300 or cme@aacr.org.

Awardee Profiles

2024 AACI Distinguished Scientist Award



Paula D. Bos, PhD

VCU Massey

Comprehensive Cancer Center

Paula D. Bos, PhD, is an associate professor of pathology and the co-leader of the Cancer Biology Program at VCU Massey Comprehensive Cancer Center.

A major focus of her research is the identification of tumor-promoting mechanisms by regulatory Treg cells, a subset of CD4 lymphocytes prominently found in tumors and associated with poor prognoses. Her findings, published in 2020 in *Cell Reports*, validate the potential for adoptive transfer therapeutics using macrophages programmed with the IFN- γ protein to effectively treat breast cancer.

Dr. Bos's pioneering work has garnered her recognition and funding, including a Susan G. Komen Career Catalyst Award (2018), a V Foundation Scholar Award (2018), an American Cancer Society Scholar Award (2021), and a National Institutes of Health MERIT (R37) Award, and her expertise in the tumor microenvironment, its progression, and metastatic dissemination, has earned local, national, and global recognition. Her work promises to have an enduring impact on cancer research and ultimately cancer care as she investigates tumor growth mechanisms and explores potential immunotherapies for cancer control.

Recent AACI Distinguished Scientist honorees include Drs. Patricia LoRusso; Elizabeth M. Jaffee; Judy E. Garber; William G. Kaelin, Jr.; Douglas R. Lowy; Charles Perou; Carl June; and James Allison.

Awardee Profiles

2024 AACI Champion for Cures Award



Friends of Dartmouth Cancer Center and the Prouty *Dartmouth Cancer Center*

Since its founding in 1977, Friends of Dartmouth Cancer Center (the Friends) has raised more than \$65 million to support cancer research and patient and family support services. The group's signature fundraiser is the Prouty, a family-friendly event combining cycling, walking, rowing, golf, and other sports. The Friends raises

roughly \$8 million each year through small gifts from more than 12,000 individual donors.

Funds raised by the Friends fuel cancer research by providing seed funding to scientists to support the discovery of new and better ways to treat cancer and enhance survivorship. On average, every \$1 the Friends invests in research leads to a 12:1 return in investment in terms of additional funding from other sources.

For 47 years, the Friends has helped fuel innovative cancer research; fund education programs; provide equipment for research labs; improve access to clinical trials; and support initiatives to care for the whole patient - including a new food pantry. Funds from the Prouty also launched and sustain the Complementary Care Program, which offers a variety of free activities to enhance the well-being of patients and caregivers, including meditation, yoga, massage, art therapy, music therapy, creative writing classes, and support groups.

The Friends is led by a volunteer Board of Directors, consisting of 18 to 22 community members, including current and former patients, family members of patients, and business leaders. The Friends also includes more than 15 volunteer committees.

The Champion for Cures Award was established as an annual award in 2018 to recognize philanthropic support of AACI cancer centers. Previous recipients are Dana Dornsife, Lazarex Cancer Foundation; Pelotonia; Sidney and Caroline Kimmel; Phil and Peggy Knight; the Jon M. and Karen Huntsman family; and Richard and Susan Rogel.

2024 AACI Cancer Health Equity Award



Edith P. Mitchell, MD, MACP, FCCP, FRCP (London)

*Sidney Kimmel
Comprehensive Cancer Center at
Jefferson*

The 2024 Cancer Health Equity Award will be presented posthumously to **Edith P. Mitchell, MD, MACP, FCCP, FRCP (London)**, with Dr. Mitchell's family accepting the award on her behalf.

Prior to her death in January 2024, Dr. Mitchell served as enterprise vice president for cancer disparities at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Jefferson, director of the Center to Eliminate Cancer Disparities and associate director for diversity affairs at SKCCC, and clinical professor of medicine and medical oncology at Thomas Jefferson University's Sidney Kimmel Medical College.

Cancer health disparities were central to her research, which examined factors affecting clinical trial participation and barriers to accrual among underrepresented populations. Dr. Mitchell and a group of primary-care physicians established a program to increase colorectal cancer screening in the SKCCC catchment area. Dr. Mitchell also established the CDC Breast and Cervical Screening Project at SKCCC and helped operate a mobile unit that offered free mammograms throughout the U.S.

A retired U.S. Air Force Brigadier General, Dr. Mitchell was the first woman physician in history to attain the rank. She completed 36 years in the armed forces and worked with the Veterans Affairs Hospital in Philadelphia. She was also the first African American and the first female faculty member to receive the Jefferson Achievement Award in Medicine from Thomas Jefferson University.

Dr. Mitchell was the 116th president of the National Medical Association and served on several National Institutes of Health and National Cancer Institute committees. She was the recipient of numerous awards for military service and community health; was appointed a member of the President's Cancer Panel in 2019; received the 2021 AACR Minorities in Cancer Research-Jane Cooke Wright Lectureship; and was inducted into the National Historical Black College Hall of Fame.

The AACI Cancer Health Equity Award was established in 2021. Previous recipients are Drs. Amelie Ramirez, Electra D. Paskett, and Robert A. Winn.

Keynote Speaker



Lawrence H. Einhorn, MD

*Indiana University
Melvin and Bren Simon
Comprehensive Cancer Center*

Lawrence H. Einhorn, MD, a distinguished professor in the Indiana University School of Medicine Department of Medicine, has witnessed and participated in major milestones in the fight against cancer over the past 50 years. He will present the opening keynote, “Development of Innovative Therapies in Oncology With

Testis Cancer as a Model,” during the 2024 AACI/CCAF Annual Meeting.

Dr. Einhorn is widely known for his success in medical oncology and in the development of a curative treatment for testicular cancer, the most common cancer in young men. His most recognized accomplishment is his development in 1974 of a chemotherapy regimen for disseminated testicular cancer that revolutionized the results of therapy and is responsible for a dramatic improvement in the cure rate of what previously had been a fatal disease. Thanks to Dr. Einhorn's efforts and those of Dr. John P. Donohue, more than 95 percent of all patients with this disease who seek treatment at a major medical center now survive. This includes Dr. Einhorn's first patient, John Cleland, who passed away in 2022 – 48 years after his treatment.

Dr. Einhorn rose to greater prominence when he used his novel treatment paradigm to treat Lance Armstrong, cancer advocate and seven-time winner of the Tour de France. With Dr. Einhorn's treatment, Armstrong survived stage 3 testicular cancer, which initially presented with abdominal, brain, and lung metastases.

In addition to his own career accomplishments, Dr. Einhorn will highlight more recent progress, including the development of personalized targeted therapies and major advances in immunotherapy.

Exhibitors

The Association of American Cancer Institutes (AACI) and the American Association for Cancer Research (AACR) express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Advarra

Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, site and sponsor technology, and clinical trial experience software, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions enable the collaboration, transparency, and speed to optimize trial operations, ensure patient safety and engagement, and reimagine clinical research while improving compliance.

Caris Life Sciences®

Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. To learn more, follow us on Twitter (@CarisLS).

ConcertAI

ConcertAI is a leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies.

Deep 6 AI

Deep 6 AI is the leader in precision research software, connecting all research stakeholders in an AI-powered, real-time, data-driven, collaborative ecosystem. Our Precision Matching software mines millions of patient records, including “unstructured” physician notes, to pinpoint eligible study patients in real time. Deep 6 AI eliminates months of manual data validation to de-risk and accelerate clinical trials.

Florence

Florence Healthcare is a leading provider of Site Enablement solutions that streamline clinical research operations and improve collaboration among research sites, sponsors, and CROs. With a focus on driving innovation and enhancing the trial site experience through site enablement, Florence Healthcare is committed to closing the cure acceleration gap and revolutionizing the clinical trial industry.

Exhibitors

Huron

Huron's cancer and clinical research team builds upon our company's vast experience in helping universities, hospitals, and research institutes accelerate change, build their future, and drive lasting and measurable results through a combination of strategy, expertise, and creativity. Our dedicated team has focused on cancer centers for over 10 years and continues to be led by experts with 20-plus years of front-line cancer center experience and a deep understanding of the National Cancer Institute (NCI) landscape.

Huron has worked with nearly every academic institution nationwide to enhance their research enterprise by improving clinical research operations, streamlining research administration, providing strategic planning guidance, and preparing for NCI designation. Our experts bring the depth of expertise required to enable centers to quickly improve performance across multiple dimensions through tailored approaches and solutions that meet each unique center's goals, issues, and environment.

IgniteData

IgniteData's market-leading data transfer technology, Archer, is transforming the future of clinical trials, bringing all the benefits of fast, accurate EHR-to-EDC data transfer to sites and sponsors alike.

- Validated and in use by sites and sponsors internationally
- Enterprise-level eSource-to-Sponsor data transfer platform designed for research sites
- System-agnostic - integrates seamlessly with all major EHRs and research systems
- Scalable by design - ideal for multiple studies and multiple sites
- Purpose-built mapping engine matches and normalizes data, providing export-ready data without the effort
- Easy-to-use and loved by researchers: the clinician is always in control
- Rapid eSource-to-Sponsor data transfer - up to 96% faster than manual methods
- Can map and transfer 100% of vital signs and labs data
- Significantly reduces Source Data Verification (SDV) and query resolution time
- Hassle-free implementation and streamlined licensing process

Meet the IgniteData team and visit our booth.

InfoReady

InfoReady's software platform eliminates the workflow challenges associated with promoting opportunities, processing applications, routing and review processes, and sharing results for research at health care organizations and higher education institutions. Our software is simple to configure, easy to use, and provides insights to enhance outcomes. InfoReady is used to manage the competitions around limited submission grants, internal and seed funding, pilot grants, prizes, fellowships, scholarships, administrative approvals, awards, nominations, and much more.

Inspirata

Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. We are a Cancer Informatics company that offers several innovative software solutions leveraging scalable AI and NLP in the clinical trial and cancer registry spaces. Refined over more than a decade in collaboration with the National Cancer Institute and used by hundreds of health care institutions globally, our proprietary NLP engine is at the heart of Nurse Navigator and Trial Navigator, our powerful clinical trial matching solutions, and our industry-leading E-Path suite of cancer registry automation solutions.

LeanTaaS

LeanTaaS is the market leader in providing AI-powered and cloud-based capacity management, staffing, and patient flow software and transformation services for health systems. Partnering with over 1,000 hospitals and centers, our iQueue products for operating rooms, infusion centers, and inpatient units use Lean principles and AI/ML predictive and prescriptive analytics to increase patient access, decrease wait times, reduce health care delivery costs, and improve revenue.

Merck

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Mint Medical

Mint Medical specializes in software solutions for standardized computer-assisted review of medical images and clinical data. Having started as a spin-off of German Cancer Research Center, Mint Medical has supported evidence-based medicine in oncology for over a decade by providing the foundation for imaging and clinical data interoperability. Its cutting-edge software platform mint Lesion™ enables the consistent collection, visualization, and analysis of structured, AI-ready data in clinical routine, clinical trials, and research. mint Lesion is an intelligent radiology assistant which automatically generates structured reports using standardized read procedures and built-in criteria guidelines (e.g., RECIST, Lugano, etc. for clinical trials and PI-RADS, LI-RADS, etc. for routine). It guides the reader through the case, alleviating the burden of ensuring criteria conformity, longitudinal transparency of disease, and reproducibility of measurements. mint Lesion is an FDA-cleared medical device used by university hospitals, cancer centers, iCROs, and pharma companies around the world.

Exhibitors

nCartes

nCartes is a transformational EHR-to-EDC cloud software platform. nCartes enables clinical research sites and sponsors to harness electronic health record systems to automate data capture for clinical trials, patient registries, cell manufacturing, and more. nCartes sites report time and cost reductions in study data entry of as much as 50% while also materially reducing data entry mistakes and related work associated with source data verification. nCartes is a proud collaborator with the **SWOG Cancer Research Network** whose sites have also experienced considerable success with nCartes on SWOG trials. To learn more, please stop by the nCartes exhibit or contact info@ncoup.com.

RealTime eClinical Solutions

RealTime eClinical Solutions is a leading eClinical technology provider reshaping the landscape of clinical trials with its comprehensive eClinical platform. Purpose-built for clinical research sites, site networks, AMCs, sponsors, and CROs, the platform goes beyond traditional CTMS to empower research and business workflows for modern-day clinical trials from trial award and study start-up through to trial execution. RealTime helps organizations manage the research and business of clinical trials, together, with software solutions including CTMS, eReg/eISF, eSource, participant payments (SitePay/GlobalPay), engagement solutions (Text, eConsent, and MyStudyManager™ Participant Portal), and Devana for pipeline management, business intelligence, and process and performance metrics.

STAT Informatic Solutions

STAT Informatic Solutions was created in 2007 by a team of long-term health information specialists to bring greater expertise and efficiencies to the areas of health information that effect patient care and the ability of physicians to have all information available about their patients the moment they walk in the door.

STAT's main areas of expertise include:

1. Record Retrieval Services - STAT created the RRS program to assist health care facilities to collect and upload information for new/returning patients utilizing our long-term experience, state of the art technology, and dedication to your patients. The retrieval includes medical records, imaging, and pathology slides or digitization of pathology and upload of this information directly to the EMR, imaging system, and pathology as determined with the facility. Also included is the software, RetrievalTrack, to track all information through the process from Patient Access Personnel to upload.

-
2. Document Imaging Services - STAT works with customers all across the nation to accommodate and assist with the move to a totally digital environment. STAT will integrate all your documents, regardless of type, to your preferred digital storage system or one that STAT can provide. Whether you need a back-file conversion, scan on demand, or conversion of digital media, STAT will develop workflows to provide all information in the most current digital environment for quick and easy access. Conversion of large format documents, including blueprints, is a great way to reduce the space the documents consume, providing data in an easy-to-access, and legible, format for your team.
 3. Cyber Downtime Health Information Strategy - STAT has created a program to assist health care systems to implement a downtime strategy in the event of a cyber attack. The program was created to help health systems begin to upload records within days of systems coming up instead of months. Proactive strategy planning enables the team to be prepared for recovery.
 4. Cyber Clean-Up Services - Once systems have come back up after a facility or system cyber attack, STAT takes the paper medical records created during downtime, and, with our advanced technologies, uploads all downtime records into the EMR so expedited access for patient care and coding may begin.

Verily

Verily is an Alphabet company that combines a data-driven, people-first approach to bring the promise of precision health to everyone, every day. Within Verily, the Clinical Studies Platforms organization provides solutions to generate the data and evidence needed to inform critical treatment and care decisions. This function evolved from Project Baseline, a multi-year research initiative, and is composed of leading experts in clinical science, RWD and RWE, technology, and user experience. The team delivers research-ready datasets that bring together a wide variety of different sources of health data to represent the longitudinal health journey of individuals. To do this, Verily focuses on understanding permissions, enabling traceability, and solving for markedly different data integrity and quality.

Our solutions bring together evidence generation, care delivery, and care management in a connected and reinforcing ecosystem built to advance precision health, connecting research participants with studies and offering tools to improve clinical research. This includes **SignalPath**, a new state-of-the-art clinical trial management system (CTMS) that was built by researchers, for researchers, to dramatically improve the ease, quality, efficiency, and profitability of trial execution.

Exhibitors

VCU Massey Comprehensive Cancer Center

VCU Massey Comprehensive Cancer Center was designated by the National Cancer Institute (NCI) in 1975 and was awarded comprehensive status in 2023. Massey's vision is to be a premier community-focused cancer center leading the nation in cancer health equity research and ensuring optimal health outcomes for all. Massey is committed to developing and testing new cancer therapies through one of the largest clinical trials offerings in Virginia, its Minority/Underserved NCI Community Oncology Research Program, and the NCI Cancer Screening Research Network (CSRN) as a coordinating site for the CSRN.

Yunu, Inc.

Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu's aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management.

Support

Acknowledgment of Commercial Support

The Association of American Cancer Institutes (AACI) and the American Association for Cancer Research (AACR) express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- **Novartis**
 - **Pfizer**
 - **Varian**
-

Acknowledgment of Programmatic Support

AACI gratefully acknowledges the following organizations for providing program and exhibit support:

- **Adminformatics**
- **Advarra**
- **Caris Life Sciences®**
- **ConcertAI**
- **Deep 6 AI**
- **Flatiron**
- **Florence**
- **Huron**
- **IgniteData**
- **InfoReady**
- **Inspirata, Inc.**
- **LeanTaaS**
- **Lilly**
- **Medidata**
- **Merck**
- **Mint Medical**
- **nCartes**
- **RealTime (Complion)**
- **STAT Informatic Solutions**
- **The Ohio State University Comprehensive Cancer Center – The James**
- **Triomics**
- **VCU Massey Comprehensive Cancer Center**
- **Verily Life Sciences**
- **Yunu, Inc.**

Disclosure of Financial Relationships

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark; C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	Relationships	Type	Role
Adsul	Prajakta	No Relationships		Speaker
Anderson	Jaime	No Relationships		Staff
Arthur	Ronald	No Relationships		Staff
Balch	Alan	No Relationships		Program Committee, Speaker
Bhargava	Rohit	No Relationships		Program Committee
Boppart	Stephen	PhotoniCare	OBO	Speaker
Bos	Paula	No Relationships		Speaker
Cameron	Carrie	No Relationships		Speaker
Carpten	John	Roche, Break Through Cancer, Stand Up to Cancer, American Association for Cancer Research	IC, IC, IC, FO	Program Committee
Cattani	Dana	No Relationships		Speaker
Chang	Jenny	Eli Lilly	IC	Program Committee
Dalton	William	No Relationships		Speaker
Ehlers	Shawna	No Relationships		Speaker
Einhorn	Lawrence	Amgen, Indiana University	S, E	Speaker
Fisher	Nicholas	No Relationships		Program Committee
Freeman	Harold	No Relationships		Speaker
Fuld Nasso	Shelly	No Relationships		Speaker
Gonzalez	Brian	Elly Health, Moffitt Cancer Center, Society of Behavioral Medicine	IC, E, IC	Speaker
Hernández-Aldama	Loriana	Merck, Novartis	IC, IC	Program Committee, Speaker
Johnson	Wenora	Eisai, American College of Obstetricians and Gynecologists, Bristol Myers Squibb, Flatiron Health	IC, IC, IC, IC	Speaker
Kibbe	Warren	No Relationships		Speaker
Kwong	Gabriel	Port Therapeutics, Glympse Bio	S, S	Speaker
Law	Wendy	No Relationships		Speaker
Lee	Kelvin	No Relationships		Program Committee
Lieu	Christopher	Pfizer, Genentech, Amgen	IC, GC, IC	Program Committee
Longtin	Krista	No Relationships		Speaker

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products or services used by or on patients.

Last Name	First Name	Relationships	Type	Role
Luray	Jenny	No Relationships		Speaker
Mesecar	Andrew	No Relationships		Program Committee
Overby	Amy	No Relationships		Speaker
Pegher	Jennifer	No Relationships		Program Committee, Speaker
Ptak	Krzysztof	No Relationships		Speaker
Rathmell	Kimryn	Incyte Corporation, Merck	GC, IC	Speaker
Ruppin	Eytan	No Relationships		Speaker
Sanchez	Yolanda	Dan L Duncan Cancer Center at Baylor College of Medicine, Sanford Burnham Prebys Medical Discovery Institute, Washington University School of Medicine in St. Louis, University of Southern California, Salk Institute Cancer Center, The Jackson Laboratory, University of Nebraska Medical Center, Dartmouth College, Dartmouth College, Dartmouth College	IC, IC, IC, IC, IC, IC, IC, IC, E, E	Program Committee
Schaum	Julie	No Relationships		Program Committee, Speaker
Schilz	Aaron	No Relationships		Speaker
Shaw	Reuben	No Relationships		Speaker
Shumate	Kate	No Relationships		Speaker
Sivendran	Shanthi	American Cancer Society, Oncologist	E, IC	Speaker
Sleckman	Barry	No Relationships		Program Committee
Tuveson	David	No Relationships		Speaker
Vander Heiden	Matthew	Auron Therapeutics; iTeos Therapeutics; Sage Therapeutics, Inc.; Droia Ventures; Agjios Pharmaceuticals, Inc.	IC, IC, IC, IC, IC	Speaker
Williams	Erin	Eli Lilly and Company	IC	Speaker
Williams	Kevin	No Relationships		Speaker
Wynne	Robert	No Relationships		Speaker
Zack	Travis	Xyla	IC	Speaker
Zafirovski	Alex	No Relationships		Program Committee, Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.



CME-Approved Sessions Worksheet

2024 AACI/CCAF Annual Meeting | October 20-22 | CME-Approved Sessions Worksheet

Date	Time (central)	Session Title	Approved Credits	Credits
Sunday 10/20/2024	1:45 - 2:45 pm	Keynote: Development of Innovative Therapies in Oncology With Testis Cancer as a Model	1.0	
	3:15 - 4:15 pm	12th Annual AACI PCLl Meeting AI and Big Data: A New Era in Cancer Care and Research	1.0	
	4:15 - 5:15 pm	Bioengineering in Cancer: Into the Future	1.0	
Maximum Approved Credits for Sunday			3.0	Total:
Monday 10/21/2024	8:30 - 9:45 am	Mental Health: The Silent Side Effect of Cancer	1.25	
	9:45 - 10:45 am	Mapping the Future of Patient Navigation	1.0	
	11:00 - 11:15 am	AACI Awards Presentation	.25	
	11:15 am - 12:15 pm	AACI Distinguished Scientist: Dr. Paula D. Bos	1.0	
	1:45 - 2:45 pm	Establishing Academic Integrity and Public Trust in the Misinformation Era	1.0	
	2:45 - 3:45 pm	Drivers of Innovation and Technology to Improve Cancer Outcomes	1.0	
	4:00 - 5:00 pm	Beyond Nuts and Bolts: Evaluating the Shifting Landscape of the CCSG	1.5	
Maximum Approved Credits for Monday			6.5	Total:
Tuesday 10/22/2024	8:00 - 8:30 am	Maximizing Resources to Advance Clinical Research	1.0	
	9:00 - 10:00 am	Update on the NCI Cancer Centers Program	1.0	
	10:15 - 11:15 am	Strategies for Enhancing Diversity in a Shifting Legal Landscape	1.0	
	11:15 am - 12:15 pm	National Cancer Institute Director's Report	1.0	
Maximum Approved Credits for Tuesday			4.0	Total:
Maximum CME Credits Approved			13.5	Total:

The Most Powerful Liquid Biopsy Assay Ever Developed

Caris Assure™ is a revolutionary, multi-cancer assay that utilizes a novel circulating Nucleic Acids Sequencing (cNAS) approach that provides increased clinical confidence with deep molecular insights from a minimally invasive blood sample.



Every Gene for Every Patient: Whole Exome & Whole Transcriptome Sequencing from Blood

- ▶ Tumor-Derived, Incidental Germline*, and Incidental CH Variant Detection

Be Sure with Caris Assure.

Expect more from liquid biopsy profiling and discover innovation that delivers at www.CarisLifeSciences.com/Assure.

**Not a replacement for comprehensive germline testing. Incidental pathogenic alterations are reported, including ACMG recognized cancer genes. Negative results do not imply the patient does not harbor a germline mutation.*

Caris Assure™ is intended for patients with previously diagnosed solid malignant neoplasms when tissue is not feasible and is to be used by qualified healthcare professionals. RNA results are intended for investigational purposes only. Not available in all locations.



©2024 Caris MPI, Inc. All rights reserved. TN5023 v1 04 JUN 2024

WE ARE TURNING CLINICAL TRIAL EXPECTATIONS ON THEIR HEAD

Scan the QR code to register interest about being involved in a Lilly clinical trial as an investigator.



Reference: 1. Unger JM, Shulman LN, Factor MA, et al. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. *J Clin Oncol*. 2024;42(18):2139-2148.

Lilly champions a simple and no-cost approach to protocol-required tumor profiling

3

Lilly aims to allow a cycle of standard-of-care treatment prior to enrollment without making the patient ineligible

2

Lilly aims to pay for all protocol-required medicines and procedures

1

Did you know only 7% of US cancer patients enroll in clinical trials? Here's what we're doing to address some enrollment barriers in phase III clinical trials to make them more inclusive and accessible.

(VV-OTHR-US-DEL-3688) 09/2024 © Lilly USA, LLC 2024. All rights reserved.

Lilly A MEDICINE COMPANY

The Ohio State University Comprehensive
Cancer Center – Arthur G. James Cancer Hospital
and Richard J. Solove Research Institute

— *is a proud sponsor of the* —

AACI and CCAF Annual Meeting

The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

cancer.osu.edu



TRIOMICS

Clinical data is vital for research, enabling accurate patient-study matching and informing **EDC/eCRF responses**. However, lack of standardization and interoperability, along with crucial information hidden in clinical notes, impedes the development of automated systems, leading to labor-intensive manual procedures like **chart reviews** and **double data entry from EHR to EDC**.


Triomics leads in solving these problems, employing a solution that harnesses commonly adopted data standards and **AI systems, such as language models**. Our technology transforms manual tasks like eligibility chart reviews and EDC data entry from EHRs into **efficient, automated processes, resulting in time and effort savings of over 80%**.


Learn more about us at:
www.triomics.com

**Fifty years of research,
innovation and impact**



Unconditionally committed to
keeping loved ones in our lives





yunu

Trial imaging workflow that actually works

Yunu delivers a mature and scalable cloud-based platform for trial imaging workflow that 25% of NCI-designated cancer centers already trust.

Yunu customers can:

- Reduce imaging data error rates as high as 50% down to < 1%
- Increase trial volumes by an average of 40% in the first year



**QUICK &
EASY TASK
MANAGEMENT**



**CONNECTED
IMAGING
ASSESSMENTS**



**COMPLETE
OPERATIONS &
AUDIT READINESS**



**STEP-BY-STEP
GUIDANCE**

**Saves 80% of Cancer Center
+ 50% of Imaging Assessment Time**

Listen in on Yunu's
AACI Imaging Accuracy
Panel Podcast



yunu.io



info@yunu.io

SAVE THE DATES



2025 CADEX Conference

January 29-31, 2025

*Coronado Island Marriot Resort & Spa
Coronado, CA*



2025 AACI Leadership Diversity and Development Workshop

March 11-12, 2025

*Loews Chicago O'Hare Hotel
Rosemont, IL*



2025 AACI/AACR Hill Day

May 22, 2025

Washington, DC



17th Annual AACI CRI Meeting

June 23-25, 2025

*Loews Chicago O'Hare Hotel
Rosemont, IL*



2025 AACI/CCAF Annual Meeting

The 2025 DEI Summit, hosted by AACI in partnership with the American Cancer Society and the Cancer Center DEI Network, will be held in conjunction with this meeting.

October 19-21, 2025

*Salamander Hotel
Washington, DC*

DEEP 6 AI

Co-sponsor of the
AAGI/CCAF 2024
Hospitality Event on 10/21


Stop by our booth to learn about our AI-Powered Patient Recruitment & RWD

Visit deep6.ai to learn more

The Huron difference in cancer and clinical research



Huron has worked with **nearly every NCI-designated cancer center** and has served as the go-to consulting firm for **cancer centers, health systems, networks, and consortia**.



We provide support with:

- Clinical research strategy and operational performance
- Clinical trials management systems
- Education, training, and building academic futures
- NCI designation and achieving your goals
- And more!

For more information, visit [our website](https://www.huron.com), stop by our booth, or contact:

Beverly Ginsburg, Managing Director

✉ bginsburg@hcg.com ☎ 617-429-4714

Thank you

to the 2024 AACI Tech Gold
members





www.aaci-cancer.org

